Research suggests GLP-1 medications can help women manage obesity and may improve reproductive health in some cases. However, pregnancy precautions, muscle loss and weight regain after treatment remain important concerns.
GLP-1 weight loss medications are changing how doctors treat obesity in women, offering new options for managing appetite and body weight. However, emerging research shows that the benefits must be considered alongside concerns about fertility, muscle loss and maintaining results after treatment ends.
A study published October 7, 2026, found that structured nutritional support and a wellness application helped participants regain less weight after stopping GLP-1 medications. The findings add to growing research examining what happens when people discontinue treatments such as semaglutide.
Separate scientific reviews suggest these medications may also improve certain reproductive outcomes among women with polycystic ovary syndrome, or PCOS. However, evidence remains limited, and GLP-1 medications are not approved as fertility treatments.
Doctors emphasize that treatment decisions should consider individual health conditions, pregnancy plans and the possibility of needing long-term weight management.
Why Weight Loss Can Be Difficult for Women
Obesity is increasingly understood as a chronic condition influenced by genetics, hormones, metabolism, environment and brain signaling.
Traditional advice to reduce food intake and increase exercise can help, but it does not always produce lasting weight loss.
When people lose weight, their bodies respond through biological mechanisms designed to conserve energy.
Levels of leptin, a hormone associated with energy stores and feelings of fullness, generally decline. Meanwhile, levels of ghrelin, a hormone that stimulates hunger, may increase.
These changes can make people feel hungrier while their bodies require fewer calories than before.
The combination helps explain why maintaining weight loss can become more difficult over time.
Women also experience hormonal changes that can influence where the body stores fat.
After menopause, declining estrogen levels are associated with increased abdominal fat and changes in body composition.
These changes do not make weight loss impossible, but they can complicate efforts to manage body weight while preserving strength and overall health.
Dr. Olesya Gurova, an endocrinologist quoted in Russian media coverage, has emphasized that obesity treatment should address these biological factors rather than relying on willpower alone.
However, treatment recommendations must also account for the risks and benefits of specific medications.
How GLP-1 Medications Work
GLP-1 receptor agonists imitate the activity of glucagon-like peptide-1, a hormone released by the intestine after eating.
The hormone helps regulate appetite and blood sugar by influencing signals between the digestive system, pancreas and brain.
Medications such as semaglutide act on GLP-1 receptors, helping people feel full sooner and reducing hunger.
Semaglutide is marketed under different brand names, including Wegovy for weight management and Ozempic for certain patients with type 2 diabetes.
Tirzepatide, sold as Zepbound for weight management and Mounjaro for diabetes, works through both GLP-1 and GIP hormone pathways.
These medications can produce substantial weight loss when combined with appropriate nutritional care and physical activity.
However, they do not eliminate the need for long-term health management.
Patients may experience nausea, vomiting, diarrhea, constipation and other gastrointestinal problems.
More serious complications can occur, including gallbladder disease, pancreatitis and dehydration-related kidney problems.
Doctors evaluate these risks alongside potential benefits before prescribing treatment.
Research Raises Questions About Muscle Preservation
One concern surrounding GLP-1 medications is whether people lose too much muscle while reducing body weight.
Muscle supports physical strength, mobility and metabolic health, making preservation important during weight loss.
An analysis of the STEP 1 clinical trial examined changes in body composition among adults receiving semaglutide.
Researchers found that participants taking the medication experienced a 19.3% reduction in total fat mass and a 27.4% reduction in visceral fat mass.
However, total lean body mass also decreased by 9.7%.
The proportion of body weight made up of lean tissue increased because fat mass declined more substantially.
That distinction is important.
An increase in the percentage of lean mass does not mean people are gaining muscle or avoiding muscle loss.
Lean body mass also includes water, organs and other tissues, so changes in lean mass cannot be treated as direct measurements of muscle loss.
Researchers are investigating approaches that may help preserve physical function during treatment.
These include resistance exercise, sufficient dietary protein and regular assessment of nutritional status.
Patients experiencing substantial weight loss may benefit from discussing strength, mobility and dietary intake with their healthcare professionals.
GLP-1 Drugs May Affect Fertility
The relationship between GLP-1 medications and reproductive health has attracted increasing scientific attention.
Excess body weight and metabolic conditions can contribute to irregular ovulation in some women.
PCOS is one condition in which hormonal imbalances and insulin resistance may interfere with menstrual cycles and fertility.
Because GLP-1 medications can improve weight and metabolic measures, researchers have investigated whether they can also improve reproductive outcomes.
A systematic review published in the European Journal of Endocrinology in 2026 examined GLP-1 treatment among women with PCOS.
The review considered changes in weight, metabolism and reproductive health.
Other studies have reported improvements in menstrual regularity and ovulation among some patients receiving these medications.
However, research has not established that GLP-1 medications reliably improve fertility across all women or that they should be prescribed specifically to achieve pregnancy.
Many studies have involved relatively small groups or have used different medications and treatment schedules.
More research is needed to determine which patients might benefit and whether improvements persist after treatment stops.
Pregnancy Requires Special Precautions
Although metabolic improvements may help some women who previously experienced difficulty conceiving, GLP-1 medications require particular caution during pregnancy planning.
These drugs are not recommended for weight loss during pregnancy.
Human pregnancy safety data remain limited, and animal studies have raised concerns about potential harm to fetal development.
U.S. prescribing information for semaglutide instructs patients to discontinue the medication at least two months before a planned pregnancy.
The waiting period reflects the time needed for the drug to leave the body.
Women who are planning to conceive should discuss treatment changes with a healthcare professional rather than independently adjusting prescription medication.
This is particularly important for patients with diabetes, because blood sugar management remains essential before and during pregnancy.
Another concern involves contraception.
Tirzepatide can reduce the effectiveness of oral hormonal contraceptives because it affects how quickly the stomach empties.
U.S. prescribing information recommends using a nonoral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and four weeks after each dose increase.
These precautions demonstrate why fertility-related counseling should be part of treatment decisions for women of reproductive age.
Study Examines Weight Regain After Stopping Treatment
One of the biggest challenges facing people who use GLP-1 medications is maintaining weight loss after discontinuation.
A pilot randomized controlled trial published in Obesity Science & Practice on October 7 examined strategies that might reduce weight regain.
The researchers enrolled 39 adults who had previously lost weight using GLP-1 therapy.
Participants were recruited through obesity medicine clinics in Dallas and El Paso, Texas, and an online research recruitment service.
They were randomly assigned to one of three groups.
The first group received usual care, while the second used a digital wellness application.
The third group received medically tailored meals designed to support weight management.
Participants monitored their weight remotely using connected scales over four months.
The research team wanted to examine whether structured support could help participants maintain progress after medication withdrawal.
Meal Programs and Wellness App Show Promise
The study found meaningful differences in estimated weight regain between the groups.
Participants receiving usual care regained an estimated 10.75% of their body weight during the four-month period.
Those using the wellness application regained an estimated 3.60%, while participants receiving medically tailored meals regained 3.58%.
Both interventions were associated with substantially less regain than usual care.
The application provided behavioral support, including guidance on eating habits, physical activity and weight monitoring.
Participants receiving meals had access to portion-controlled food prepared around nutritional goals.
The findings suggest that practical support may help people manage the return of hunger and other challenges following GLP-1 discontinuation.
Kelseanna Hollis-Hansen, a researcher at the Tufts University Food is Medicine Institute and corresponding author of the study, emphasized the importance of protecting the progress patients make during treatment.
The research supports further investigation into approaches that combine medication with ongoing nutritional and behavioral care.
However, it does not establish that either intervention will consistently prevent long-term weight regain.
Small Study Has Important Limitations
The trial involved only 39 participants, making it too small to establish how the interventions would perform across a broad population.
Most participants were women, and recruitment was concentrated in two Texas metropolitan areas.
The research also followed participants for just four months.
That period provides useful information about early weight regain but cannot establish whether the improvements would continue for a year or longer.
Another limitation was the remote study design.
Participants used connected scales and completed questionnaires, which may have affected how consistently they engaged with the interventions.
The researchers found no statistically significant differences between groups in reported diet quality, perceived health, treatment adherence or satisfaction.
Although the weight findings were promising, the study was intended primarily to assess the feasibility and acceptability of the interventions.
Larger studies with longer follow-up periods are needed to determine which strategies are most effective and affordable.
Long-Term Care Remains Important
The growing use of GLP-1 medications has changed expectations about obesity treatment, but experts caution against viewing the drugs as a permanent solution for everyone.
Weight regain after stopping treatment is common because the biological factors influencing appetite and body weight may return.
For some patients, continued medication may be appropriate under medical supervision.
Others may discontinue treatment because of cost, insurance restrictions, side effects or pregnancy plans.
Healthcare professionals can help patients prepare for those changes by discussing nutritional support, physical activity and realistic expectations.
Women who are considering pregnancy may need additional planning to balance reproductive goals with metabolic health.
Preserving muscle, maintaining adequate nutrition and monitoring other health conditions are also important throughout treatment.
The October study provides early evidence that structured support may reduce weight regain after GLP-1 therapy ends. Its findings will need confirmation in larger trials before doctors can determine how widely these approaches should be recommended.
For women considering GLP-1 medications, the central decision involves more than the amount of weight they might lose. Fertility plans, medication safety, body composition and a realistic strategy for maintaining long-term health all deserve attention before treatment begins.
IMAGE: voltamax / Pixabay